Drugs / Imipenem-Cilastatin
Imipenem-Cilastatin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT02149329 | Dec 2014 → Aug 2019 | hematopoietic and lymphoid cell neoplasm, neutropenia | Amsterdam UMC, location VUmc | Completed | Met primary |
| Comparator or background therapy6 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03445195 Background | Jan → May 2018 | acute pyelonephritis | Entasis Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT06847126 Comparator | Feb 2025 → Jun 2026 overdue | liver abscess (disease) | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 3 | NCT06059846 Comparator | Dec 2023 → Jan 2025 | acute pyelonephritis | Spero Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00589693 Comparator | Apr 2008 → Jun 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
| Phase 3 | NCT00619710 Comparator | Feb 2001 → Dec 2003 | abscess, cellulitis, skin infection | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imipenem-cilastatin | “The intravenous-group will receive Beta-lactam antimicrobials (i.e Piperacillin-Tazobactum 4.5g q 8 hourly or Ceftriaxone 1g q 12 hourly or Meropenem 1g q 8 hourly or...” NCT06847126 ↗6“Imipenem-Cilastatin*” NCT02099240 ↗ |
| Known as | IMI | “Eighty patients with complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), were randomized 2:1 to receive SUL-DUR at 1 g/1 g intravenously (i.v.) or...” PMID 31843995 ↗ Feb 2020 |
| Known as | tienam (imipenem-cilastatin) | “tienam (imipenem-cilastatin)” NCT02149329 ↗ |
| Route | Intravenous | “route=intravenously.” NCT00589693 ↗ |